<code id='0EC2FB66A4'></code><style id='0EC2FB66A4'></style>
    • <acronym id='0EC2FB66A4'></acronym>
      <center id='0EC2FB66A4'><center id='0EC2FB66A4'><tfoot id='0EC2FB66A4'></tfoot></center><abbr id='0EC2FB66A4'><dir id='0EC2FB66A4'><tfoot id='0EC2FB66A4'></tfoot><noframes id='0EC2FB66A4'>

    • <optgroup id='0EC2FB66A4'><strike id='0EC2FB66A4'><sup id='0EC2FB66A4'></sup></strike><code id='0EC2FB66A4'></code></optgroup>
        1. <b id='0EC2FB66A4'><label id='0EC2FB66A4'><select id='0EC2FB66A4'><dt id='0EC2FB66A4'><span id='0EC2FB66A4'></span></dt></select></label></b><u id='0EC2FB66A4'></u>
          <i id='0EC2FB66A4'><strike id='0EC2FB66A4'><tt id='0EC2FB66A4'><pre id='0EC2FB66A4'></pre></tt></strike></i>

          fashion

          fashion

          author:explore    Page View:63
          George Yancopoulos on the 2024 Breakthrough Summit East stage.
          George Yancopoulos on the 2024 Breakthrough Summit East stage STAT

          George Yancopoulos is in touch with his teenage self.

          After 35 years as head scientist at Regeneron Pharmaceuticals, Yancopoulos has led the development of 12 approved medicines, turning a once-fledgling company into the $100 billion global drugmaker it is today. And you can trace a straight line back to the childhood fascination with science he fostered growing up in Woodside, Queens.

          advertisement

          “My high school science project was about regenerating neurons, and ‘Regeneron’ is a contraction of ‘regenerating neurons,’” Yancopoulos said at the STAT Summit East on Thursday. “In some ways I’m still working on my high school science project.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Device maker Teleflex to acquire urology company for $600M
          Device maker Teleflex to acquire urology company for $600M

          AdobeTeleflexannouncedplansonWednesdaytoacquirePaletteLifeSciences,themakerofaslateofgel-basedproduc

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          Biogen says it will cut costs by $700 million, slash 1,000 jobs

          StevenSenn/APBiogenannouncedanewroundofcostcutsTuesday,sayingthatitplanstosave$700millioninoperating